强化他汀治疗超高龄缺血性卒中患者的疗效观察

目的:探讨超高龄缺血性卒中患者应用强化他汀类药物治疗的疗效和安全性。方法:164例超高龄缺血性卒中患者随机分为强化组(阿托伐他汀40 mg/d)80例和对照组(阿托伐他汀20 mg/d)84例,比较2组治疗14 d后血脂及NIHSS评分变化情况,比较2组随访2年后mRS评分、终点事件及不良反应事件的发生情况。结果:治疗14 d后,2组LDL-C血清水平和LDL-C达标率差异均具有统计学意义(P=0.033;P=0.032),2组NIHSS评分差异无统计学意义(P=0.112)。随访2年后,强化组的mRS评分优于对照组(P=0.042),总终点事件发生率低于对照组(P=0.040),2组不良事件发生率的差异无统计学意义(P=0.492)。结论:对于超高龄缺血性卒中患者,强化他汀治疗可安全有效地达到更佳的降脂效果。

Efficacy of Intensive Statin Therapy in Extreme Elderly Patients with Ischemic Stroke

To investigate efficacy and safety of intensive statin therapy in extreme elderly patientswith ischemic stroke. Methods: 164 extreme elderly patients with ischemic stroke were randomly divided intogroups intensive(atorvastatin 40 mg/d, n=80) and control(atorvastatin 20 mg/d, n=84). The blood lipid level andNIHSS score of the two groups were compared 14 days after treatment. Occurrence of endpoint events and adverse reactions were observed by clinical follow-up survey. Results: 14 days after treatment, there was a significant difference between the two groups in serum low density lipoprotein cholesterol (LDL-C) levels and controlrate of LDL-C (P=0.033; P=0.032). There was no difference in NIHSS score (P=0.112). In the 2-year follow-up,mRS and occurrence of total endpoint events in the intensive group were lower than those in the control group(P=0.042; P=0.040). No difference was observed in rates of adverse events (P=0.492). Conclusion: For extremeelderly patients with ischemic stroke, intensive statin therapy can safely and efficiently reduce blood lipid level .